RxDoctor Payments Data

Nacole Diaz, APRN

Family · Covington, LANPI 1376926428

Payments from drug & device makers

$11,384in general payments, 2019–2025

Across 541 payments — averaging $21.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$848
  • Blueprint Medicines Corporation$673
  • Johnson & Johnson$642
  • Merck$639
  • Bristol Myers Squibb$591
  • E.r. Squibb & Sons, L.L.C.$570
  • plus $7K from 54 others

What the payments were for

  • Consulting fees$4744%
  • Food & beverage$10,69194%
  • Education$2202%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis48$848
Blueprint Medicines Corporation7$673
Johnson & Johnson(2 entities)37$642
Merck33$639
Bristol Myers Squibb33$591
E.r. Squibb & Sons, L.L.C.25$570
Pfizer37$548
AstraZeneca(2 entities)25$457
Takeda Pharmaceuticals U.S.A., Inc.16$340
Sanofi16$307
Incyte Corporation13$305
GSK11$299
Exelixis Inc.10$296
Daiichi Sankyo Inc.12$293
Genentech USA, Inc.14$270
AbbVie11$265
Eisai Inc.13$253
Seagen Inc.10$251
Astellas Pharma US Inc11$230
Amgen11$198
Regeneron Healthcare Solutions, Inc.9$186
Beigene USA, Inc.7$152
Ipsen Biopharmaceuticals, Inc7$147
Stemline Therapeutics Inc.8$143
Gilead(2 entities)8$140
Novocure Inc.1$137
Pharmacyclics LLC, An Abbvie Company7$128
Bayer7$126
Coherus Oncology, Inc.1$125
Adaptive Biotechnologies Corporation6$122
Array Biopharma Inc6$122
Pharmaessentia USA Corporation4$108
Sanofi-aventis U.S. LLC1$99
Lilly USA, LLC5$84
Servier Pharmaceuticals LLC4$84
AVEO Pharmaceuticals, Inc.4$83
Boehringer Ingelheim3$81
Mirati Therapeutics, Inc.4$76
Jazz Pharmaceuticals Inc.4$67
Sobi, Inc4$66
G1 Therapeutics, Inc.3$55
Beone Medicines USA, Inc.3$52
Pharmacosmos Therapeutics Inc.3$51
Springworks Therapeutics, Inc.3$49
Morphosys, US Inc.3$41
Immunocore Limited1$38
Tempus AI, Inc2$37
ADC Therapeutics America, Inc.2$34
Sumitomo Pharma America, Inc.2$33
Caris MPI, Inc.2$33
Puma Biotechnology, Inc.2$31
Myovant Sciences Inc.2$30
EMD Serono, Inc.2$30
Spectrum Pharmaceuticals Inc.2$28
Karyopharm Therapeutics Inc.2$28
Menarini Silicon Biosystems, Inc.1$24
Myriad Genetic Laboratories, Inc.1$22
Recordati_rare_diseases_inc.1$22
Nuvation Bio Inc.1$21
Biogen1$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,384 in reported general payments places this provider in the 95th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$4,633
Medicare patients
31
Services billed
47

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban13$10,685
EliquisApixaban13$7,564
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen45$2,670
Megestrol Acetate18$2,034
ValacyclovirValacyclovir Hcl61$2,033
Potassium Chloride37$1,739
Ondansetron OdtOndansetron86$1,302
Fluconazole46$982
Tamoxifen Citrate24$867
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen46$806
Oxycodone Hcl13$796
Levofloxacin12$768
Letrozole32$637
Prochlorperazine Maleate46$532
Dexamethasone15$459

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$642$10,68513 claims
PfizerEliquis$548$7,56413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,610 family providers in Louisiana.

Other family in Covington

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →